5 Reports on Skin Cancer Patients May Have Missed

September 15, 2020

CURE® compiled a roundup of five recent reports patients with skin cancer may have missed.

CURE® takes a look at these 5 of the most recent updates and developments in skin cancer that patients may have missed.

These reports include the investigation of a health gap in skin cancer, as well as how patients perceive the use of artificial intelligence for skin cancer screening.

  • Patients appear open to the idea of using artificial intelligence (AI) to help in screening for skin cancer, however many patients stress the need to preserve the patient-physician relationship if implemented, according to study results published in JAMA Dermatology.
  • Promising results of a single-institution, retrospective study examining the use of Libtayo (cemiplimab-rwlc) in the first line of treatment for patients with locally advanced cutaneous squamous cell carcinoma (CSCC) has led some experts to believe that the drug could help prevent potentially disfiguring surgeries in this patient population.
  • As the treatment landscape for melanoma continues to evolve, scientists will likely focus more on the logistics of T-cell therapies and how to deliver them effectively across many modalities, according to Dr. Jason Luke, director of the Cancer Immunotherapeutics Center at UPMC and the University of Pittsburgh.
  • Strategies for shortening the time from diagnosis until surgery for Black patients are essential for reducing racial disparities in melanoma outcomes, according to results published in the Journal of the American Academy of Dermatology.
  • Adjuvant Tafinlar (dabrafenib) and Mekinist (trametinib) elicited a greater than 50% relapse-free survival (RFS) rate in patients with resected, stage 3 BRAF V600E/K-mutant melanoma, according to findings from a five-year analysis of the phase 3 COMBI-AD trial presented during the 2020 ASCO Virtual Scientific Program.

x